Product Information

BANZEL 40 MG/ML SUSPENSION is a brand product labeled by Eisai Inc., priced at $3.6486 per ML under NDC 62856058446. Its NADAC has been published 665 times since Nov 28, 2013.

FDA first approved this application on Mar 3, 2011. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the rufinamide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

BANZEL 40 MG/ML SUSPENSION

rufinamide
$3.6486per ML
High Outlier

Strength

40 mg/mL

Manufacturer

Eisai Inc.

NDC

62856058446

Classification

Brand

Dosage Form

SUSPENSION

Route

ORAL

Effective Date

8/19/2026

Active Ingredients

RUFINAMIDE

Approval Type

New Drug (NDA)

FDA Application

NDA201367

FDA Approved

3/3/2011

TE Code

AB

On Market Since

3/3/2011

Price Statistics

The NADAC for BANZEL 40 MG/ML SUSPENSION has been published 665 times since Nov 28, 2013, and over the history we have for it it has risen 153.8%. The table below summarizes its recorded NADAC range and movement.

Current price$3.6486 per ML
All-time high$3.7207 (Feb 15, 2023)
All-time low$1.4378 (Nov 28, 2013)
52-week high$3.6567
52-week low$3.6452
Median price$3.5103
Average price$3.0967
Largest weekly change+10.0% (Aug 20, 2014)
Weeks tracked665
Tracking sinceNov 28, 2013

Price History

1W

+0.0%

1M

+0.0%

3M

+0.0%

6M

+0.1%

1Y

-0.1%

3Y

-0.6%

5Y

-0.1%

All

+153.8%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the rufinamide market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Related Drugs

Same classification

No related drugs found.

Frequently asked questions

What is the NADAC price of BANZEL 40 MG/ML SUSPENSION?

The current National Average Drug Acquisition Cost (NADAC) for BANZEL 40 MG/ML SUSPENSION, manufactured by Eisai Inc., is $3.6486 per ML (NDC 62856058446), effective Aug 19, 2026.

How has the price of BANZEL 40 MG/ML SUSPENSION changed over time?

Over the history we have for it, the NADAC for BANZEL 40 MG/ML SUSPENSION has risen 153.8%. It has been tracked across 665 weekly CMS publications since Nov 28, 2013.

What are the highest and lowest recorded NADAC prices for BANZEL 40 MG/ML SUSPENSION?

Since Nov 28, 2013, the NADAC for BANZEL 40 MG/ML SUSPENSION has ranged from a low of $1.4378 (Nov 28, 2013) to a high of $3.7207 (Feb 15, 2023), with a median of $3.5103 per ML.

Are there cheaper alternatives to BANZEL 40 MG/ML SUSPENSION?

No other NADAC-published product currently shares the active ingredient and strength of BANZEL 40 MG/ML SUSPENSION in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures BANZEL 40 MG/ML SUSPENSION?

BANZEL 40 MG/ML SUSPENSION (NDC 62856058446) is labeled by Eisai Inc., and CMS classifies it as a brand product.